BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Gain Information How Well Dexpanthenol Derma Cream Helps the Face Skin to Recover After Cosmetic Lasering
Not Applicable
Completed
- Conditions
- ErythemaSkin Recovery
- Interventions
- Drug: BAY207543 (Bepanthol)Other: Semisolid vaseline
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT03852563
- Locations
- 🇧🇷
Medcin Instituto da Pele, Sao Paulo, Brazil
A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Face Skin to Recover After Cosmetic Lasering
Phase 4
Completed
- Conditions
- Skin RecoveryErythema
- Interventions
- Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)Other: Semisolid vaseline
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT03853538
- Locations
- 🇧🇷
Medcin Instituto da Pele, Sao Paulo, Brazil
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45164
- Registration Number
- NCT03847181
- Locations
- 🇬🇧
Many facilities, Many Sites, United Kingdom
4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness
Not Applicable
Completed
- Conditions
- Rosacea
- Interventions
- Drug: Coppertone, BAY1183345
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 35
- Registration Number
- NCT03841032
- Locations
- 🇺🇸
The Education & Research Foundation, Inc., Lynchburg, Virginia, United States
PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Other: myBETAappOther: PEAKDrug: Betaferon, BAY86-5046Device: BETACONNECT
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 79
- Registration Number
- NCT03808142
- Locations
- 🇩🇪
Many locations, Multiple Locations, Germany
An Observational Study on Incidence, Natural History and Treatment Patterns of Venous Thromboembolism in Taiwan
Completed
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 104215
- Registration Number
- NCT03799016
Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT03789890
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Rogaratinib (BAY1163877) in Chinese Patients
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1
- Registration Number
- NCT03788603
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
End-stage Renal Disease (ESRD) Pilot Study
Phase 1
Completed
- Conditions
- Renal Dialysis
- Interventions
- Drug: BAY1213790Drug: 0.9% sodium chloride solution
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 55
- Registration Number
- NCT03787368
- Locations
- 🇪🇸
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
🇧🇪CHU de Charleroi Hôpital civil, Lodelinsart, Hainaut, Belgium
🇺🇸California Institute of Renal Research - Chula Vista, Chula Vista, California, United States
Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3000
- Registration Number
- NCT03784391
- Locations
- 🇦🇷
Many locations, Multiple Locations, Argentina
© Copyright 2025. All Rights Reserved by MedPath